Conmed opened higher at $51.43, compared with its previous close of $50.77. In the last trading session, the stock traded between $50.17 and $51.43. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Conmed is now worth
$ 33.39
Resulting in a loss of
$ 66.61 (66.61%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
0%
Hold
100%
Sell
0%
Markets Today
Today's Change
$-0.32 (-0.63%)
Day High
$51.43
Day Low
$50.17
Day Open
$51.43
Prev Close
$50.77
Volume
1,68,921
1W Return
-5.98%
1M Return
11.22%
3M Return
1.68%
6M Return
43.20%
1Y Return
12.84%
Fundamentals
Market Cap ($ Mn)
1,504
PE Ratio
27.02
PB Ratio
1.44
PEG Ratio
34.89
ROE
4.72%
ROCE
5.06%
EPS (TTM)
$0.66
Investment Returns
1 Week
-5.98%
1 Month
11.22%
3 Months
1.68%
6 Months
43.20%
9 Months
19.18%
Financials
Quarterly
All values in $ Mn
342.3
Jun 25
337.9
Sep 25
373.2
Dec 25
317.0
Mar 26
343.5
Jun 26
335.6
Sep 26
Updates
2Oct
CONMED to report Q3 2026 financial results on October 28
CONMED Corporation will report Q3 2026 results on October 28, 2026. Conference call scheduled for 4:30 pm ET on the same day. Webcast replay available approximately one hour after the call ends.
1mo ago
30Jul
Conmed Raises FY2026 Adj EPS Guide to $4.48-$4.60
Conmed raises FY2026 adjusted EPS guidance to $4.48-$4.60, beating the $4.34 estimate. Sales outlook is narrowed to $1.358B-$1.373B from a previous range of $1.350B-$1.375B, aligning closely with the $1.362B market consensus.
3mo ago
22Jul
CONMED expands AirSeal compatibility to Intuitive da Vinci 5
CONMED Corporation announced that its AirSeal Robotic Solution is now indicated for use with Intuitive’s 8 mm hex cannulas as part of the da Vinci 5 platform. This expands compatibility to include Intuitive’s da Vinci X, Xi, and 5 systems. The move aims to enhance patient outcomes and procedural efficiency.
3mo ago
9Jul
BMO Capital initiates coverage on Conmed with $36 price target
BMO Capital initiates coverage on Conmed with a Market Perform rating and announces a price target of $36.
4mo ago
3Jul
CONMED Corporation to report Q2 2026 results on July 29
CONMED Corporation is set to report its Q2 2026 financial results on July 29, 2026, followed by a conference call with management. The company provides surgical devices for specialties like orthopedics and general surgery. Access to the call and webcast replay is available through its investor relations portal.
4mo ago
29Jun
B of A Securities downgrades Conmed to Underperform
B of A Securities analyst Travis Steed has downgraded Conmed from Neutral to Underperform. The firm maintains the price target at $40.
